Follow The Filings

DAFNA Capital Management LLC Nathan Fischel

Los Angeles, CA 20 processed 13Fs on this site, 2021 Q3 to 2026 Q2

  • $524M
  • 88 holdings
  • 2026 Q2
  • +19.1% QoQ
  • Top 5 40.2%

Nathan Fischel's biggest moves in 2026 Q2 were opening Kymera Therapeutics and Adlai Nortye, adding to Denali Therapeutics and Nektar Therapeutics, trimming Revolution Medicines and SPDR S&P Biotech ETF, and selling out of DAWN and Kalvista Pharmaceuticals.

Portfolio

2026 Q2, filed 8/14/2026, top 12 of 88 holdings

Top 5 40.2%, top 10 56.2%

  1. RVMD, Revolution Medicines 20.1%
  2. XBI, SPDR S&P Biotech ETF 5.9%
  3. CMPS, Compass Pathways 5.4%
  4. STXS, Stereotaxis 4.5%
  5. NKTR, Nektar Therapeutics 4.3%
  6. DNLI, Denali Therapeutics 3.6%
  7. IDYA, Ideaya Biosciences 3.5%
  8. ATRC, Atricure 3.2%
  9. XENE, Xenon Pharmaceuticals 2.9%
  10. CYTK, Cytokinetics 2.8%
  11. RCUS, Arcus Biosciences 2.6%
  12. ASND, Ascendis Pharma A/s 2.5%
  13. Other 38.7%

AUM over time

2026 Q2 $524M +19.1% QoQ
2021 Q3: $377M 2021 Q3: $377M
Q3 2021
2021 Q4: $398M, +5.6% QoQ 2021 Q4: $398M, +5.6% QoQ
Q4
2022 Q1: $384M, −3.5% QoQ 2022 Q1: $384M, −3.5% QoQ
Q1 2022
2022 Q2: $367M, −4.4% QoQ 2022 Q2: $367M, −4.4% QoQ
Q2
2022 Q3: $372M, +1.4% QoQ 2022 Q3: $372M, +1.4% QoQ
Q3
2022 Q4: $355M, −4.6% QoQ 2022 Q4: $355M, −4.6% QoQ
Q4
2023 Q1: $334M, −5.9% QoQ 2023 Q1: $334M, −5.9% QoQ
Q1 2023
2023 Q2: $366M, +9.6% QoQ 2023 Q2: $366M, +9.6% QoQ
Q2
2023 Q3: $321M, −12.3% QoQ 2023 Q3: $321M, −12.3% QoQ
Q3
2023 Q4: $417M, +29.9% QoQ 2023 Q4: $417M, +29.9% QoQ
Q4
2024 Q1: $439M, +5.3% QoQ 2024 Q1: $439M, +5.3% QoQ
Q1 2024
2024 Q2: $419M, −4.6% QoQ 2024 Q2: $419M, −4.6% QoQ
Q2
2024 Q3: $423M, +1.0% QoQ 2024 Q3: $423M, +1.0% QoQ
Q3
2024 Q4: $393M, −7.1% QoQ 2024 Q4: $393M, −7.1% QoQ
Q4
2025 Q1: $353M, −10.2% QoQ 2025 Q1: $353M, −10.2% QoQ
Q1 2025
2025 Q2: $362M, +2.5% QoQ 2025 Q2: $362M, +2.5% QoQ
Q2
2025 Q3: $405M, +11.9% QoQ 2025 Q3: $405M, +11.9% QoQ
Q3
2025 Q4: $431M, +6.4% QoQ 2025 Q4: $431M, +6.4% QoQ
Q4
2026 Q1: $440M, +2.1% QoQ 2026 Q1: $440M, +2.1% QoQ
Q1 2026
2026 Q2: $524M, +19.1% QoQ 2026 Q2: $524M, +19.1% QoQ
Q2

Latest book

2026 Q2 2026 Q1, filed 14 Aug, long equity only

Download CSV Download Excel All activity
RVMD, Revolution Medicines 20.09% Reduce −3.1% 562,630 $187.28 $105M −18,048 +$49M
XBI, SPDR S&P Biotech ETF 5.93%, was 9.25% Reduce −38.3% 196,505 $158.25 $31M −122,000 −$9.6M
CMPS, Compass Pathways 5.43% Reduce −16.8% 2,011,952 $14.15 $28M −406,930 +$15M
STXS, Stereotaxis 4.49% Hold 13,680,554 $1.72 $24M — —
NKTR, Nektar Therapeutics 4.24%, was 2.70% Add +92.7% 318,380 $69.81 $22M +153,202 +$10M
DNLI, Denali Therapeutics 3.62%, was 1.39% Add +132.0% 739,014 $25.72 $19M +420,514 +$13M
IDYA, Ideaya Biosciences 3.53% Add +4.3% 497,240 $37.27 $19M +20,500 +$2.6M
ATRC, Atricure 3.19% Hold 597,431 $27.98 $17M — —
XENE, Xenon Pharmaceuticals 2.89% Hold 250,772 $60.36 $15M — —
CYTK, Cytokinetics 2.79%, was 3.26% Reduce −20.9% 171,998 $85.19 $15M −45,499 +$317K
RCUS, Arcus Biosciences 2.60% Reduce −0.5% 441,829 $30.83 $14M −2,000 +$4M
ASND, Ascendis Pharma A/s 2.47% New 48,469 $266.72 $13M +48,469 +$13M
NBIX, Neurocrine Biosciences 1.86%, was 2.12% Reduce −18.2% 57,769 $168.53 $9.7M −12,846 +$433K
AXGN, Axogen 1.84%, was 1.88% Reduce −16.4% 208,960 $46.19 $9.7M −41,000 +$1.4M
PODD, Insulet 1.80%, was 0.52% Add +469.2% 61,870 $152.25 $9.4M +51,000 +$7.1M
EWTX, Edgewise Therapeutics 1.76%, was 0.80% Add +102.1% 226,819 $40.63 $9.2M +114,583 +$5.7M
BCAX, Bicara Therapeutics 1.61%, was 1.91% Reduce −32.4% 284,955 $29.69 $8.5M −136,778 +$72K
NDAQ, iShares Nasdaq Biotech Indx 1.54%, was 2.39% Reduce −31.4% 42,595 $190.19 $8.1M −19,500 −$2.4M
SNDX, Syndax Pharmaceuticals 1.40%, was 1.16% Add +54.2% 335,255 $21.86 $7.3M +117,900 +$2.3M
MPLT, Maplight Therapeutics 1.17% Hold 171,006 $35.84 $6.1M — —
LRMR, Larimar Therapeutics 1.17%, was 2.08% Reduce −1.0% 2,008,164 $3.05 $6.1M −21,000 −$3M
IPSC, Century Therapeutics 1.12%, was 1.25% Reduce −1.4% 2,400,458 $2.45 $5.9M −33,895 +$379K
DXCM, DexCom 1.11% Hold 86,279 $67.35 $5.8M — —
IMVT, Immunovant 1.10% Reduce −0.7% 149,524 $38.53 $5.8M −1,000 +$2M
INGN, Inogen 1.04% Hold 845,179 $6.45 $5.5M — —
TNDM, Tandem Diabetes Care 1.02% Hold 355,208 $15.09 $5.4M — —
ALKS, Alkermes 1.01%, was 1.12% Reduce −27.4% 101,266 $52.39 $5.3M −38,216 +$374K
STOK, Stoke Therapeutics 0.82% Hold 130,875 $32.72 $4.3M — —
ALLO, Allogene Therapeutics 0.79%, was 0.76% Add +46.0% 2,000,000 $2.08 $4.2M +629,882 +$817K
BCRX, Biocryst Pharmaceuticals 0.76%, was 0.93% Reduce −7.0% 400,248 $10.00 $4M −30,000 −$93K
LKFT, Lakefront Biotherapeutics 0.74% Hold 130,175 $29.98 $3.9M — —
KIDS, Orthopediatrics 0.69%, was 0.35% Add +97.7% 189,130 $19.13 $3.6M +93,471 +$2.1M
CYBN, Cybin 0.65%, was 0.54% Add +3.2% 514,061 $6.61 $3.4M +15,700 +$1M
RAPP, Rapport Therapeutics 0.60% Hold 75,000 $41.67 $3.1M — —
KYMR, Kymera Therapeutics 0.59% New 27,000 $114.67 $3.1M +27,000 +$3.1M
PRQR, Proqr Therapeutics 0.54%, was 0.58% Reduce −2.4% 1,530,361 $1.86 $2.8M −37,200 +$307K
NGNE, Neurogene 0.53%, was 0.26% Add +57.2% 89,032 $31.45 $2.8M +32,397 +$1.7M
ANL, Adlai Nortye 0.53% New 239,553 $11.50 $2.8M +239,553 +$2.8M
PRCT, Procept Biorobotics 0.52% Hold 120,000 $22.58 $2.7M — —
AQST, Aquestive Therapeutics 0.51%, was 0.35% Add +75.3% 645,915 $4.16 $2.7M +277,500 +$1.2M
CLDX, Celldex Therapeutics 0.49% Hold 68,518 $37.21 $2.5M — —
GPCR, Structure Therapeutics 0.48% Hold 46,500 $53.67 $2.5M — —
ALGN, Align Technology 0.45%, was 0.58% Reduce −6.7% 14,000 $168.66 $2.4M −1,000 −$210K
VKTX, Viking Therapeutics 0.44% Hold 59,516 $39.01 $2.3M — —
NGEN, Nervgen 0.41% New 1,050,000 $2.06 $2.2M +1,050,000 +$2.2M
BHVN, Biohaven 0.39%, was 1.63% Reduce −83.7% 137,593 $14.88 $2M −708,142 −$5.1M
MAZE, Maze Therapeutics 0.37%, was 0.24% Add +85.7% 65,000 $29.84 $1.9M +30,000 +$895K
ALEC, Alector 0.35% Hold 908,351 $2.01 $1.8M — —
LXEO, Lexeo Therapeutics 0.33% Hold 377,059 $4.66 $1.8M — —
PROF, Profound Medical 0.33%, was 0.39% Reduce −1.0% 260,360 $6.65 $1.7M −2,645 +$27K

Showing top 50 of 88 by value

Exits / last held

Gone since 2026 Q1, shown at their last reported size.

Stock % of portfolio Recent activity Shares Reported price* Value Share change $ change
DAWN 4.77% Exit 0 $21.44 $21M −978,463 −$21M
Kalvista Pharmaceuticals 1.22% Exit 0 $20.13 $5.4M −267,402 −$5.4M
ASND, Ascendis Pharma A/s 1.21% Exit 0 $228.72 $5.3M −23,177 −$5.3M
FULC, Fulcrum Therapeutics 0.36% Exit 0 $7.67 $1.6M −205,000 −$1.6M
Engene 0.29% Exit 0 $6.81 $1.3M −187,353 −$1.3M
SCYX, Scynexis 0.23% Exit 0 $0.9172 $997K −1,086,956 −$997K
ORIC, Oric Pharmaceuticals 0.22% Exit 0 $9.57 $945K −98,724 −$945K
ZBIO, Zenas Biopharma 0.19% Exit 0 $19.55 $831K −42,500 −$831K
NAMS 0.15% Exit 0 $32.00 $640K −20,000 −$640K
KPTI, Karyopharm Therapeutics 0.06% Exit 0 $5.57 $255K −45,800 −$255K
NMRA, Neumora Therapeutics 0.03% Exit 0 $1.96 $137K −70,000 −$137K

Weight bar: held both quarters added sold at this quarter’s reported price

* Reported price is value ÷ shares from the 13F as of period end, not a live market quote. Weight % is each long-equity position ÷ full 13F AUM, so rows may not sum to 100% when the filing includes options or other non-equity (excluded from this table). Share change and $ change are vs 2026 Q1. Click a column header to sort, or New, Hold, Add or Reduce to bring those moves to the top. Exit opens the last-held block below.

Filings history

20 periods, with AUM normalized

Newest 13Fs
Period Holds AUM QoQ Form Filed Filing ID
2026 Q2 88 $524M +19.1% 13F-HR 8/14/2026 000138993326000006
2026 Q1 83 $440M +2.1% 13F-HR 5/15/2026 000138993326000004
2025 Q4 77 $431M +6.4% 13F-HR 2/17/2026 000138993326000002
2025 Q3 75 $405M +11.9% 13F-HR 11/14/2025 000138993325000008
2025 Q2 76 $362M +2.5% 13F-HR 8/14/2025 000138993225000011
2025 Q1 83 $353M −10.2% 13F-HR 5/15/2025 000138993325000002
2024 Q4 82 $393M −7.1% 13F-HR 2/14/2025 000138993225000004
2024 Q3 84 $423M +1.0% 13F-HR 11/14/2024 000138993224000020
2024 Q2 83 $419M −4.6% 13F-HR 8/14/2024 000138993224000016
2024 Q1 72 $439M +5.3% 13F-HR 5/15/2024 000138993224000012
2023 Q4 76 $417M +29.9% 13F-HR 2/14/2024 000138993224000004
2023 Q3 75 $321M −12.3% 13F-HR 11/14/2023 000138993223000010
2023 Q2 73 $366M +9.6% 13F-HR 8/14/2023 000138993323000008
2023 Q1 72 $334M −5.9% 13F-HR 5/15/2023 000138993323000006
2022 Q4 79 $355M −4.6% 13F-HR 2/14/2023 000138993323000002
2022 Q3 87 $372M +1.4% 13F-HR 11/14/2022 000138993322000010
2022 Q2 90 $367M −4.4% 13F-HR 8/15/2022 000138993322000008
2022 Q1 94 $384M −3.5% 13F-HR 5/16/2022 000138993322000006
2021 Q4 87 $398M +5.6% 13F-HR 2/14/2022 000138993322000002
2021 Q3 80 $377M — 13F-HR 11/15/2021 000138993321000011

About

DAFNA Capital Management LLC

20 processed 13Fs on this site, 2021 Q3 to 2026 Q2

Entity
DAFNA Capital Management LLC
Notable person
Nathan Fischel
Location
Los Angeles, CA
All SEC filings
View on sec.gov